Related Experiment Video
Updated: Dec 17, 2025
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Challenges in Chagas Disease Drug Development
Amanda F Francisco1, Shiromani Jayawardhana1, Francisco Olmo1
1Department of Infection Biology, London School of Hygiene and Tropical Medicine Keppel Street, London WC1E 7HT, UK.
Abstract:
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps in our knowledge of disease pathogenesis, parasite biology and drug activity. Nevertheless, several factors have come together to create a more optimistic scenario. Drug-based research has become more systematic, with increased collaborations between the academic and commercial sectors, often within the framework of not-for-profit consortia. High-throughput screening of compound libraries is being widely applied, and new technical advances are helping to streamline the drug development pipeline. In addition, drug repurposing and optimisation of current treatment regimens, informed by laboratory research, are providing a basis for new clinical trials. Here, we will provide an overview of the current status of Chagas disease drug development, highlight those areas where progress can be expected, and describe how fundamental research is helping to underpin the process.
Insights
Developing new treatments for Chagas disease (caused by *Trypanosoma cruzi*) is crucial due to limited current options. Recent systematic research and collaborations offer a more optimistic outlook for effective drug development.
Area of Science:
- *Trypanosoma cruzi* infection
- Chagas disease pathogenesis
- Antiparasitic drug discovery
Background:
- Chagas disease, caused by *Trypanosoma cruzi*, is a significant public health issue in Latin America.
- Current treatments for Chagas disease exhibit limited efficacy, prolonged treatment durations, and considerable toxicity.
- Progress in Chagas disease therapeutics has been hindered by incomplete understanding of disease mechanisms, parasite biology, and drug actions.
Purpose of the Study:
- To provide an overview of the current landscape of drug development for Chagas disease.
- To identify promising areas for future advancements in Chagas disease therapeutics.
- To illustrate the role of fundamental research in supporting drug development for Chagas disease.
Main Methods:
- Systematic drug-based research initiatives.
- Collaborations between academic institutions and commercial entities.
- High-throughput screening of compound libraries.
- Drug repurposing strategies.
- Optimization of existing treatment regimens.
- Leveraging laboratory research findings.
Main Results:
- Increased systematic approach to drug research for Chagas disease.
- Enhanced collaborations fostering drug development efforts.
- Application of high-throughput screening and technological advancements.
- Integration of drug repurposing and regimen optimization.
- Foundation for new clinical trials based on research.
Conclusions:
- Despite challenges, the Chagas disease drug development landscape is becoming more optimistic.
- Systematic research, collaborations, and technological advancements are accelerating progress.
- Fundamental research plays a vital role in underpinning and guiding the development of new Chagas disease therapies.
Related Concept Videos
01:28Preclinical Development: Overview
01:26Drug Discovery: Overview